About Us

French Deeptech in the field of innovative antivirals

Signia Therapeutics

Signia Therapeutics is an innovative French R&D company co-founded in April 2017 by a team of French & Canadian scientists.

Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with a proof-of-concept compound, Diltiazem, an anti-hypertensive for which a novel antiviral mechanism of action has been discovered.

Diltiazem is currently being evaluated in association with oseltamivir against influenza, in a Phase IIb multicentric clinical evaluation (FLUNEXT), and a second Phase IIb.trial, starting beginning of 2022, will evaluate Diltiazem in mild-to-moderate Covid-19 hospitalized patients.

Signia Therapeutics was laureate of the i-Lab 2017 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance. The company has also been awarded the Seal of Excellence by the EU H2020 Framework Programme for Research and Innovation in 2018.

This project has received funding from the European Union’s Horizon 2020 Research and Innovation SME Instrument (grant agreement No 826722 - SIGNIA - H2020-SMEInst-2018-2020-1) and the European Innovation Council (EIC) Accelerator grant (grant agreement No 954353 - SIGNIA -)

This project has received funding from BPI France

Signia Therapeutics was awarded with the label "French Tech Seed" in March 2019 by Pouss@LYS consortium

Legal mentions

Signia Therapeutics, Société par Actions Simplifiée au capital de 19.854 euros

Siège social : Bâtiment Adénine – 60, avenue Rockefeller – 69008 Lyon

SIRET: 82888964200017

APE 7219Z TVA FR24828889642


Tel: 33(0)478776890

Directeur de la publication: Angelita de Francisco, Présidente

Hébergeur: IONOS

Signia therapeutics.com - Copyright 2021. All right reserved.